The Catalyst Effect - RXII should be a big mover in October...

Profile: RXi Pharmaceuticals Corporation (NASDAQ:RXII)

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology based company that has evolved from a platform RNAi company. Core areas of focus are ophthalmology and dermatology in which the company is motivated to expedite development of innovative therapeutics in order to cater high-ummet medical requirements. Revolving to a product based company had been a great challenge for RXi and RXI-109, a novel ‘self-delivering’ RNAi (sd-rxRNA®) compound, has been honored being a first offering of the company as a product.

Great efficacy of the drugs manufactured by RXi has been recorded. For instance in the clinical trials, RXI-109 compound and Samcyprone™ gel have shown great improvement in the patients  who were chronically suffering from warts, surgery marks, hypertrophic scars, keloids, and Alopecia Areata. Upcoming innovations and discoveries are expected to bring a terrific revolution in the field of dermatology. The drugs are intended to bring revolution by offering research contributions for tissue repair and cell generation to cure chronic dermatological damages.

The company has great opportunities of growth even outside the fields of dermatology and ophthalmology by utilizing the scope of RXI-109 compound. Because of tremendous efficacy and flexible portfolio, the company is being expected to grow by leaps and bounds.

On results of second quarter, 2015, Mr. Geert Cauwenbergh (CEO, RXi Pharmaceuticals) signaled upcoming growth and provided positive insights to the shareholders. His speech left a favorable impact on share holders since the share price increased immediately after the CEO delivered the Q2 results speech. He shared seven core initiatives for upcoming year in order to maximize shareholder’s value. He kept emphasizing over shareholder’s value all along. Year to Date (YDT) trading volume as an average of percentage of outstanding shares is 5.17% however the same indicator for one month (on an average) is 4.42%. They remained pretty successful in winning shareholders’ trust by offering dividends for common shareholders at the end of second quarter. The company has a huge potential for buoyant growth.